Market capitalization | $135.56m |
Enterprise Value | $43.81m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.93 |
P/S ratio (TTM) P/S ratio | 12.15 |
P/B ratio (TTM) P/B ratio | 3.60 |
Sales growth (TTM) Sales growth | 210.56% |
Turnover (TTM) Turnover | $11.16m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
6 Analysts have issued a ProQR Therapeutics N.V. forecast:
6 Analysts have issued a ProQR Therapeutics N.V. forecast:
Dec '23 |
+/-
%
|
||
Turnover | 7.04 7.04 |
66%
66%
|
|
Gross income | - - |
-
|
|
EBITDA | -35 -35 |
47%
47%
|
EBIT (operating result) EBIT | -38 -38 |
45%
45%
|
Net profit | -30 -30 |
56%
56%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
Head office | Netherlands |
CEO | Daniel Boer |
Employees | 156 |
Founded | 2012 |
Website | www.proqr-tx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.